GW Pharmaceuticals PLC- (GWPH) Downgraded to “Sell” at BidaskClub

BidaskClub cut shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a hold rating to a sell rating in a report released on Tuesday, BidAskClub reports.

Several other research analysts have also commented on the company. JPMorgan Chase & Co. initiated coverage on GW Pharmaceuticals PLC- in a research report on Wednesday, January 2nd. They issued an overweight rating and a $134.00 target price for the company. ValuEngine upgraded GW Pharmaceuticals PLC- from a buy rating to a strong-buy rating in a research report on Thursday, January 10th. AltaCorp Capital reiterated an outperform rating on shares of GW Pharmaceuticals PLC- in a research report on Monday, January 7th. Guggenheim initiated coverage on GW Pharmaceuticals PLC- in a research report on Friday, February 22nd. They issued a buy rating and a $178.00 target price for the company. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $193.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $180.27.

Shares of NASDAQ GWPH opened at $165.56 on Tuesday. GW Pharmaceuticals PLC- has a fifty-two week low of $90.14 and a fifty-two week high of $182.23. The company has a quick ratio of 6.34, a current ratio of 6.66 and a debt-to-equity ratio of 0.01. The company has a market cap of $5.01 billion, a price-to-earnings ratio of -15.68 and a beta of 2.80.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($2.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.97) by $0.62. GW Pharmaceuticals PLC- had a negative return on equity of 55.88% and a negative net margin of 1,734.86%. The firm had revenue of $6.65 million during the quarter, compared to analyst estimates of $7.10 million. Equities analysts expect that GW Pharmaceuticals PLC- will post -8.56 earnings per share for the current fiscal year.

In related news, CEO Justin D. Gover sold 11,112 shares of the firm’s stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $12.45, for a total value of $138,344.40. Following the sale, the chief executive officer now owns 392,885 shares of the company’s stock, valued at approximately $4,891,418.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Justin D. Gover sold 22,620 shares of the firm’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $12.50, for a total value of $282,750.00. Following the completion of the sale, the chief executive officer now directly owns 370,445 shares in the company, valued at approximately $4,630,562.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,895,496 shares of company stock valued at $27,538,565. Insiders own 5.50% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Canada Pension Plan Investment Board raised its stake in GW Pharmaceuticals PLC- by 327.3% during the 4th quarter. Canada Pension Plan Investment Board now owns 1,175,000 shares of the biopharmaceutical company’s stock valued at $114,424,000 after acquiring an additional 900,000 shares in the last quarter. Jennison Associates LLC raised its stake in GW Pharmaceuticals PLC- by 39.2% during the 4th quarter. Jennison Associates LLC now owns 515,281 shares of the biopharmaceutical company’s stock valued at $50,183,000 after acquiring an additional 145,227 shares in the last quarter. Morgan Stanley raised its stake in GW Pharmaceuticals PLC- by 14.1% during the 3rd quarter. Morgan Stanley now owns 432,144 shares of the biopharmaceutical company’s stock valued at $74,649,000 after acquiring an additional 53,368 shares in the last quarter. Deutsche Bank AG raised its stake in GW Pharmaceuticals PLC- by 18.2% during the 4th quarter. Deutsche Bank AG now owns 270,575 shares of the biopharmaceutical company’s stock valued at $26,350,000 after acquiring an additional 41,593 shares in the last quarter. Finally, Federated Investors Inc. PA raised its stake in GW Pharmaceuticals PLC- by 14.2% during the 3rd quarter. Federated Investors Inc. PA now owns 257,300 shares of the biopharmaceutical company’s stock valued at $44,446,000 after acquiring an additional 32,000 shares in the last quarter. 79.32% of the stock is currently owned by institutional investors and hedge funds.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: What is a stock buyback?

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.